

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 2, 2011
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 2, 2011.

2. Welcome

Debbie Tapley, R.Ph., called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Jony Bolinger, MD
Kelly Jones, PharmD
Tan Platt, MD

Jim Lindsay, MD
Thomas Phillips, R.Ph.
Ed Vess, R.Ph.

Debbie Tapley, R.Ph.

SC DHHS Staff:

James M Assey, R.Ph.
Valeria Williams

Magellan Medicaid Administration:

Bryan Amick, PharmD
Mary Roberts, R.Ph.

Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 3, 2011.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug/Class
Pfizer	David Bart Lawrence, PharmD	Celebrex
AstraZeneca	Anabelle Keohane, PharmD	Vimovo
Shire Pharmaceuticals	Yolanne Hinds-Kinney, PharmD	Intuniv
Lilly	Diane Flickinger	Strattera
Merck	Vicki Star, MD	Vitreolis
Vertex Pharmaceuticals	James Strohecker, MD	Vitreolis
Taro Pharmaceuticals	Kathy Galloway	Topicort

C. Drug Classes for Review

Bryan Amick led the discussion for the following drug classes:

- Fluoroquinolones (Oral)
- Nonsteroidal Anti-Inflammatory Drugs (Oral)
- Non-Stimulant ADHD Agents
- Protease Inhibitor for Hepatitis
- Smoking Cessation Products
- Topical Acne Agents
- Topical Steroids

The chart below represents the recommendations from the P & T Committee:

FLUOROQUINOLONES	
Preferred	Non-Preferred
CIPROFLOXACIN LEVOFLOXACIN	AVELOX CIPROFLOXACIN ER FACTIVE LEVAQUIN NOROXIN OFLOXACIN PROQUIN XR

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS	
Preferred	Non-Preferred
DICLOFENAC DIFLUNISAL	ARTHROTEC CELEBREX

NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (Continued)	
Preferred	Non-Preferred
ETODOLAC	DUEXIS
FLURBIPROFEN	FENOPROFEN
IBUPROFEN	MECLOFENAMATE
INDOMETHACIN	MEFENAMIC ACID
KETOPROFEN	SPRIX
KETOROLAC	TOLMETIN
MELOXICAM	ZIPSOR
NABUMETONE	
NAPROXEN	
OXAPROZIN	
PIROXICAM	
SULINDAC	
VIMOVO	

NON-STIMULANT ADHD AGENTS	
Preferred	Non-Preferred
STRATTERA	KAPVAY
INTUNIV	

PROTEASE INHIBITOR FOR HEPATITIS	
Preferred	Non-Preferred
INCIVEK	
VICTRELIS	

SMOKING CESSATION PRODUCTS	
Preferred	Non-Preferred
CHANTIX	NICOTROL NS (NASAL)
NICOTINE GUM	NICOTROL (INHALATION)
NICOTINE PATCH	
BUPROPION SR	
NICOTINE LOZENGE	

TOPICAL ACNE AGENTS	
Preferred	Non-Preferred
AKNE-MYCIN	ACANYA
AZELEX	ACZONE
BENZAACLIN	ADAPALENE
BENZOYL PEROXIDE	ATRALIN
CLINDAGEL	BENZEFOAM
CLINDAMYCIN PHOSPHATE	CLARIFOAM EF
DIFFERIN	CLINAC BPO

TOPICAL ACNE AGENTS (Continued)	
Preferred	Non-Preferred
EPIDUO	CLINDAMYCIN/BENZOYL PEROXIDE
ERYTHROMYCIN	DUAC
RETIN-A MICRO	ERYTHROMYCIN-BENZOYL PEROXIDE
TRETINOIN	EVOCLIN
	INOVA
	NUOX
	SE BPO
	SULFACETAMIDE
	SUMAXIN TS
	TAZORAC
	VELTIN
	ZACLIR
	ZIANA

STEROIDS, TOPICAL LOW	
Preferred	Non-Preferred
ALCLOMETASONE DIPROPIONATE	DESONATE
CAPEX SHAMPOO	DESONIL + PLUS
DERMA-SMOOTHIE-FS	PEDIADERM HC / TA
DESONIDE	VERDESO
HYDROCORTISONE	

STEROIDS, TOPICAL MEDIUM	
Preferred	Non-Preferred
CLODERM	CORDRAN TAPE
FLUOCINOLONE ACETONIDE	CUTIVATE LOTION
FLUTICASONE PROPIONATE	LOCOID LIPOCREAM
HYDROCORTISONE BUTYRATE	LUXIQ
HYDROCORTISONE VALERATE	MOMEXIN
MOMETASONE FUROATE	PANDEL
	PREDNICARBATE

STEROIDS, TOPICAL HIGH	
Preferred	Non-Preferred
BETAMETHASONE DIPROPIONATE	AMCINONIDE
BETAMETHASONE VALERATE	DIFLORASONE DIACETATE
DESOXIMETASONE	HALOG
FLUOCINONIDE	KENALOG AEROSOL
FLUOCINONIDE EMOLLIENT	VANOS
FLUOCINONIDE-E	
TRIAMCINOLONE ACETONIDE	

STERIODS, TOPICAL VERY HIGH	
Preferred	Non-Preferred
CLOBETASOL EMOLLIENT	CLOBEX
CLOBETASOL PROPIONATE	HALAC
HALOBETASOL PROPIONATE	HALONATE
	OLUX-E

5. **Old Business**

None

6. **New Business**

Bryan Amick, PharmD announced his resignation from Magellan Medicaid Administration effective November 18, 2011.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Fluoroquinolones (Oral)
- Nonsteroidal Anti-Inflammatory Drugs (Oral)
- Non-Stimulant ADHD Agents
- Protease Inhibitor for Hepatitis
- Smoking Cessation Products
- Topical Acne Agents
- Topical Steroids

8. **Closing Comments**

The next meeting will be held on Wednesday, February 1, 2012, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 5:25 p.m.